Table 1.
Clinicopathologic and treatment characteristics
| No. (%) | |
|---|---|
| No. of patients | 195 |
| Median years, age | 50, range 27–84 |
| T-stage at presentation | |
| T1 | 25 (12.8) |
| T2 | 94 (48.2) |
| T3 | 61 (31.3) |
| T4d (inflammatory) | 15 (7.7) |
| Histological type | |
| Ductal | 158 (83.6) |
| Lobular | 14 (7.4) |
| Other | 17 (9.0) |
| Unknown | 6 (3.1) |
| Nottingham histological grade | |
| I | 1 (0.7) |
| II | 79 (55.6) |
| III | 62 (43.7) |
| Unknown | 53 (27.2) |
| ER-positive | 134 (68.7) |
| PR-positive | 95 (48.7) |
| HER2-positive | 62 (31.8) |
| Neoadjuvant systemic therapy | |
| Anthracycline plus taxane | 184 (94.4) |
| Anthracycline only | 7 (3.6) |
| Other | 3 (1.5) |
| Aromatase inhibitor | 1 (0.5) |
T-stage tumor size radiologically, ER estrogen receptor, PR progesteron receptor, HER2 human epidermal growth factor receptor 2